

学会発表(国内学会)

2019.05 第 59 回肝癌症例検討会

1. 直腸カルチノイド腫瘍術後 3 年 9 ヶ月で多発肝転移を発症した 1 症例
土屋淳一, 佐々木大祐, 石井将光, 四万村司, 朝倉武士, 津田享志, 小池淳樹, 大坪毅人

2019.07 第 17 回日本臨床腫瘍学会学術集会

1. 私の腫瘍内科医としてのキャリア:大学病院の立場から
中島貴子
2. <大腸がん診療における遺伝子関連検査等のガイダンス>
包括的ゲノムプロファイリング検査/リキッドバイオプシー
砂川優
3. An observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Yu Sunakawa
4. Prospective study to investigate the clinical efficacy of G-CSF for Docetaxel + Cisplatin + 5-Fluorouracil (DCF) chemotherapy in patients with esophageal squamous cell carcinoma (ESCC).
Mitsuhiro Sugawara, Chikatoshi Katada, Akinori Watanabe, Yasutoshi Sakamoto, Hiroki Hara, Hirofumi Fujii, Takako Nakajima, Takayuki Ando, Takashi Kojima, Hideki Ishijima, Ayumu Hosokawa, Yasuo Hamamoto, Manabu Muto, Makoto Tahara, Wasaburo Koizumi.
5. Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06.
Yu Sunakawa, Wataru Ichikawa, Ken Hagiwara, Masahiro Tsuda, Akinori Takagane, Hisateru Yasui, Hironaga Satake, Tadamichi Denda, Yoshihiko Segawa, Hiroaki Tanioka, Masahito Kotaka, Mitsugu Kochi, Takanori Watanabe, Masato Nakamura, Akihito Tsuji, Satoshi Tani, Yuji Negoro, Kazutoshi Tobimatsu, Masahiro Takeuchi, Masashi Fujii
6. Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer.
Masato Nakamura, Yu Sunakawa, Hiroyuki Okuyama, Masato Matsuura, Yuji Negoro, Taichi Yabuno, Takao Takahashi, Takao Tamura, Nobumichi Takeuchi, Hironaga Satake, Yuji Miyamoto, Masato Kataoka, Manabu Shiozawa, Akitaka Makiyama, Kazuma Kobayashi, Yutaro Kubota, Takashi Sekikawa, Masahiro Takeuchi, Wataru Ichikawa and Masashi Fujii

7. 2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC).

薦田正人, 山本駿, 川上武志, 三谷誠一郎, 辻靖, 伊澤直樹, 川上賢太郎, 山本祥之, 津田孝志, 他

8. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors.

Naoki Izawa, Hisae Shiokawa, Risa Onuki, Koki Hamaji, Naoki Furuya, Hiroyuki Ohashi, Tomohiro Nishi, Shigeru Kasugai, Hiroyuki Takeda, Kumiko Umemoto, Hiroyuki Arai, Ayako Doi, Yoshiki Horie, Mami Hirakawa, Takuro Mizukami, Takashi Ogura, Takashi Tsuda, Yu Sunakawa, Takako Eguchi Nakajima

学会発表(国際学会)

2019.05 American Society Clinical Oncology

1. Clinical verification of circulating tumor RNA (ctRNA) as novel pre-treatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): a biomarker study of the DEEPER trial.

Yu Sunakawa, Joshua L. Usher, Yolanda S Jaimes, Akihito Tsuji, Manabu Shiozawa, Takanori Watanabe, Hironaga Satake, Hirofumi Ota, Mitsugu Kochi, Hisatsugu Ohori, Dai Manaka, Masato Matsuura, Masahiro Takeuchi, Peter V. Danenberg, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz, Kathleen Danenberg.

2. Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.

Wataru Okamoto, Yoshiaki Nakamura, Manabu Shiozawa, Yoshito Komatsu, Tadamichi Denda, Hiroki Hara, Yoshinori Kagawa, Yukiya Narita, Hisato Kawakami, Taito Esaki, Tomohiro Nishina, Naoki Izawa, Koji Ando, Toshikazu Moriwaki, Takeshi Kato, Fumio Nagashima, Taroh Satoh, Shogo Nomura, Takayuki Yoshino, Kiwamu Akagi.

3. Genomic Alterations After EGFR Blockade in Patients with RAS Wild-Type Metastatic Colorectal Cancer: Combined Tissue and Blood-Based Analysis from SCRUM-Japan GI-SCREEN and GOZILA.

Yoshiaki Nakamura, Riu Yamashita, Wataru Okamoto, Yukiya Narita, Yoshito Komatsu, Yoshinori Kagawa, Naoki Takahashi, Taito Esaki, Takeshi Kato, Yu Sunakawa, Tadamichi Denda, Tomohiro Nishina, Atsuo Takashima, Takaaki Kobayashi, Manabu Shiozawa, Eiji Oki, Taroh Satoh, Yuta Adachi, Justin Odegaard, Takayuki Yoshino.

4. Phase I Safety and Pharmacokinetic Study of KN035, the first subcutaneously administered, novel fusion Anti-PD-L1 Antibody in Japanese Patients with Advanced Solid Tumors.

Toshio Shimizu, Takako Eguchi Nakajima, Ni Lu, Shilin Xue, Wenlian Xu, Amanda Fu, Walt Cao, Haolan Lu, David Liu, Ruiping Dong, Xiaoxiao Wang, Pilin Wang, Danming Zhu, Ting Xu, John Gongo.

2019.06 MASCC

1. Phase III Study of Comparing Dexamethasone on Day 1 with Day 1–4 with Combined Nurokinin–1 Receptor Antagonist, Palonosetron and Olanzapine in Cisplatin–based Chemotherapy:SPARED Trial
H. Minatogawa, N. Izawa, T. Kawaguchi, T. Miyaji, A. Yokomizo, Y. Horie, K. Shimomura, K. Honda, H. Morita, N. Hida, A. Tsuboya, T. Tsuda, H. Iihara, Y. Ohno, T. Yamaguchi, T. Nakajima.

2019.07 ESMO–GI

1. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second–line treatment in patients with advanced gastric cancer.
Shigenori Kadowaki, Naoki Izawa, Keiko Minashi, Tomohiro Nishina, Takeharu Yamanaka, Kei Muro, Yu Sunakawa, Shuichi Hironaka, Takeshi Kajiwara , Yutaka Kawakami, Takako Eguchi Nakajima.
2. RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti–EGFR antibodies in patients with metastatic colorectal cancer (mCRC).
Y Sunakawa, M Nakamura, M Ishizaki, M Kataoka, H Satake, M Kitazono, H Yanagisawa, Y Kawamoto, H Kuramochi, H Ohori, M Nakamura, K Takahashi, F Maeda, C Komeno, M Takeuchi, M Fujii, T Yoshino, W Ichikawa, A Tsuji.

2019.09 CSCO

1. CKN.
Toshio Shimizu , Takako EguchiNakajima, Ni Lu, Qiong Hua, Shilin Xue, Wenlian Xu, Amanda Fu, Walt Cao, Haolan Lu, David Liu, John Gong, Xiaoxiao Wang, Pilin Wang, Danming Zhu, Ting Xu.

2019.09 ESMO Congress

1. Prognostic and predictive impact on FMS–like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.
H Hasegawa, H Taniguchi, T Kato, S Fujii, H Ebi, M Shiozawa, S Yuki, T Masuishi, K Kato, N Izawa, T Moriwaki, Y Kagawa, Y Sakamoto, W Okamoto, Y Nakamura, K Yamazaki, T Yoshino.
2. Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC–08 (DELIVER trial).
Y. Sunakawa, Y. Takahashi, E. Inoue, Y. Sakamoto, R. Kawabata, H. Yabusaki, J.Matsuyama, A. Ishiguro, M. Takahashi, Y. Akamaru, Y. Kito, A. Makiyama, H.Yasui, H. Kawakami, T. Nakajima, K. Muro, R. Matoba, W. Ichikawa, M.Fujii.
3. Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2–mutated advanced gastrointestinal (GI) cancers using cell–free DNA (cfDNA) sequencing analysis in the GOZILA study.
Y. Kawamoto, Y. Nakamura, M. Ikeda, H. Bando, T. Esaki, M. Ueno, T. Nishina, Y. Kagawa, E. Oki, T. Denda, T. Mizukami, N. Takahashi, N. Okano, I. Miki, Y. Sakamoto, M. Lefterova, J. Odegaard, H. Taniguchi, C. Morizane, T. Yoshino.

1. A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer.
Shuichi Hironaka, Shigenori Kadowaki, Naoki Izawa, Tomohiro Nishina, Takeharu Yamanaka, Keiko Minashi, Kei Muro, Yu Sunakawa, Takeshi Kajiwara, Yuichiro Hayashi, Yutaka Kawakami, Takako Eguchi Nakajima.
2. The treatment strategy of the second-line chemotherapy for metastatic colorectal cancer (mCRC) patients (pts) with early progression in the first-line chemotherapy with bevacizumab (BEV), BEV beyond progression (BBP), or non-BBP.
Takeshi Kawakami, Shun Yamamoto, Seiichiro Mitani, Taito Esaki, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama, Kentaro Yamazaki, Toshiki Masuishi, Takako Eguchi Nakajima, Hiroyuki Okuda, Toshikazu Moriwaki, Narikazu Boku.
3. RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC).
Yu Sunakawa, Masato Nakamura, Masahiro Ishizaki, Masato Kataoka, Hironaga Satake, Masaki Kitazono, Hideyuki Yanagisawa, Yasuyuki Kawamoto, Hidekazu Kuramochi, Hisatsugu Ohori, Michio Nakamura, Fumiyo Maeda, Chihiro Komeno, Masahiro Takeuchi, Masashi Fujii, Takayuki Yoshino, Wataru Ichikawa, Akihito Tsuji.
4. Plasma VEGF-D and PIGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study.
Hiroya Taniguchi, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina, Yoshinori Kagawa, Naoki Takahashi, Hisateru Yasui, Tadamichi Denda, Yu Sunakawa, Kentaro Yamazaki, Taito Esaki, Hisato Kawakami, Takeshi Kato, Kazuhiro Yoshida, Atsuo Takashima, Hiroko Ohmiya, Shogo Nomura, Atsushi Ohtsu, Takayuki Yoshino.
5. Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.
Yoshiaki Nakamura, Hiroya Taniguchi, Hideaki Bando, Ken Kato, Taito Esaki, Yoshito Komatsu, Naoki Takahashi, Makoto Ueno, Yoshinori Kagawa, Tomohiro Nishina, Takeshi Kato, Yoshiyuki Yamamoto, Junji Furuse, Tadamichi Denda, Hisato Kawakami, Eiji Oki, Yu Sunakawa, Taroh Satoh, Takayuki Yoshino, Atsushi Ohtsu.
6. Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial.
Naoki Izawa, Kohei Shitara, Toshiki Masuishi, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Hiroyuki Okuda, Chihiro Kondoh, Tomohiro Nishina, Akitaka Makiyama, Hideo Baba, Hironori Yamaguchi, Masato Nakamura, Akihito Tsuji, Taito Esaki, Yoshinori Miyata, Masahito Kotaka, Takeharu Yamanaka, Takako Eguchi Nakajima, Kei Muro.

7. Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial.
- Naoki Izawa, Kohei Shitara, Toshiki Masuishi, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Hiroyuki Okuda, Chihiro Kondoh, Tomohiro Nishina, Akitaka Makiyama, Hideo Baba, Hironori Yamaguchi, Masato Nakamura, Yu Sunakawa, Kohei Akiyoshi, Mikio Sato, Kimio Yonesaka, Takayuki Yoshino, Takeharu Yamanaka, Kei Muro.

論文業績(和文)

《原著・総説・解説》

1. 腫瘍内科医に必要な緩和医療のポイント

- 臨床腫瘍プラクティス, 15(3).
- 土井綾子

2. 肝機能障害への対応

- がん免疫療法, 3(1): 24-26, 2019.
- 新井裕之, 中島貴子

3. 後方ライン治療におけるICのポイント

- 大腸癌に対するレゴラフェニブ治療, 80-84, 2019.
- 新井裕之, 中島貴子

4. がん治療における Patient-Reported Outcome

- 腫瘍内科, 2019; 25(1): 78-83.
- 土井綾子, 堀江良樹, 中島貴子

5. 分子標的治療 消化器がんにおける分子標的治療薬

- 消化器外科専門医の心得, 2019; 第1 般. 158-162.
- 伊澤直樹, 中島貴子

論文業績(英文)

《原著・総説》

1. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer

- Investigational New Drugs. 37(178): 1-9, 2019.
- Takako Eguchi Nakajima, Ayako Doi, Hiroyuki Arai, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa

2. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer

 - Gastric Cancer. 22(96):1–9, 2019.
 - Daisuke Takahari, Keisho Chin, Naoki Ishizuka, Atsuo Takashima, Keiko Minashi, Shigenori Kadowaki, Tomohiro Nishina, Takako Eguchi Nakajima, Kenji Amagai, Nozomu Machida, Masahiro Goto, Keisei Taku, Takeru Wakatsuki, Hirokazu Shoji, Shuichi Hironaka, Narikazu Boku, Kensei Yamaguchi
3. Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer

 - International Journal of Clinical Oncology. 25(143):1–42, 2019.
 - Yojiro Hashiguchi, Kei Muro, Yutaka Saito, Yoshinori Ito, Yoichi Ajioka, Tetsuya Hamaguchi, Kiyoshi Hasegawa, Kinichi Hotta, Hideyuki Ishida, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Yusuke Kinugasa, Keiko Murofushi, Takako Eguchi Nakajima, Shiro Oka, Toshiaki Tanaka, Hiroya Taniguchi, Akihito Tsuji, Keisuke Uehara, Hideki Ueno, Takeharu Yamanaka, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Michio Itabashi, Kentaro Sakamaki, Keiji Sano, Yasuhiro Shimada, Shinji Tanaka, Hiroyuki Uetake, Shigeki Yamaguchi, Naohiko Yamaguchi, Hirotohi Kobayashi, Keiji Matsuda, Kenjiro Kotake, Kenichi Sugihara
4. Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer

 - Oncology. 97(2):94–101, 2019.
 - Naoki Izawa Yu Sunakawa Ayako Doi Hiroyuki Arai Yoshiki Horie Mami Hirakawa Takuro Mizukami Takashi Ogura Takashi Tsuda Takako Eguchi Nakajima
5. Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

 - BMC Cancer. 19(1):652, 2019.
 - Hiroyuki Arai, Satoru Iwasa, Narikazu Boku, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Keiko Minashi, Shuichi Hironaka, Naoki Fukuda, Daisuke Takahari and Takako Eguchi Nakajima
6. TImmune-related genes to dominate neutrophil-lymphocyte ratio (NLR) associated with survival of cetuximab treatment in metastatic colorectal cancer

 - Drugs. 79(6):633–645, 2019.
 - 水上拓郎、伊澤直樹、中島貴子、砂川優
7. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer

 - Cancer Science. 110(11):3565–3572, 2019.
 - Tetsuya Hamaguchi, Tadamichi Denda, Toshihiro Kudo, Naotoshi Sugimoto, Takashi Ura, Kentaro Yamazaki, Hirofumi Fujii, Takeshi Kajiwara, Takako Eguchi Nakajima, Shin Takahashi, Satoshi Otsu, Yoshito Komatsu, Fumio Nagashima, Toshikazu Moriwaki, Taito Esaki, Takeo Sato, Michio Itabashi, Eiji Oki, Toru Sasaki, Marielle Chiron, Takayuki Yoshino

8. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.
-
- ESMO Open. 2019;00(00): 1–5, 2019.
 - Toshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, Hideaki Bando, Yoshito Komatsu, Eiji Shinozaki, Takako Eguchi Nakajima, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Masashi Wakabayashi, Shogo Nomura, Koji Takahashi, Hiromi Ono, Nami Hirano, Noriko Fujishiro, Nozomu Fuse, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino
9. DELIVER (JACCRO GC-08) Trial: Discover Novel Host-Related Immune-Biomarkers for Nivolumab in Advanced Gastric Cancer.
-
- Future Oncol. 15(21), 2441–2447.
 - Yu Sunakawa, Eisuke Inoue, Ryo Matoba, Hisato Kawakami, Yoshiharu Sato, Takako Eguchi Nakajima, Kei Muro, Wataru Ichikawa, Masashi Fujii
10. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.
-
- Future Oncol. 9 849.
 - Jesús García-Foncillas, Yu Sunakawa, Dan Aderka, Zev Wainberg, Philippe Ronga, Pauline Witzler, Sebastian Stintzing
11. Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy.
-
- Esophagus. 17 (1), 67–73.
 - Taniyama TK, Tsuda T, Miyakawa K, Arai H, Doi A, Hirakawa M, Horie Y, Mizukami T, Izawa N, Ogura T, Sunakawa Y, Nakajima TE.
12. Randomized phase II/III study of 5-fluorouracil/leucovorin versus 5-fluorouracil/leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G)
-
- Gastric Cancer.
 - Takako Eguchi Nakajima, Kensei Yamaguchi, Narikazu Boku, Ichinosuke Hyodo, Junki Mizusawa, Hiroki Hara, Tomohiro Nishina, Takeshi Sakamoto, Kohei Shitara, Katsunori Shinozaki, Hiroshi Katayama, Shinichiro Nakamura, Kei Muro, Masanori Terashima
13. Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients
-
- Clin Pharmacol Ther. 107(7).
 - Yutaro Kubota, Ken-Ichi Fujita, Takehiro Takahashi, Yu Sunakawa, Hiroo Ishida, Kazuyuki Hamada, Wataru Ichikawa, Takuya Tsunoda, Kazuhiro Shimada, Yusuke Masuo, Yukio Kato, Yasutsuna Sasaki
14. “Phantom Akathisia” in an Amputated Leg of a Sarcoma Patient: A Case Report
-
- Biopsychosoc Med.
 - Mayumi Ishida, Jungo Imanishi, Yasuo Yazawa, Yu Sunakawa, Tomoaki Torigoe, Hideki nishi